Patient Profile 1: A Patient With HER2+ Metastatic BC Treated With T-DXd who Develops ILD

Video

After reviewing the historical use of ADCs, panelists discuss the first patient profile of HER2+ metastatic breast cancer managed with trastuzumab deruxtecan.

Recent Videos
Image of a woman with a white shirt in front of an Oncology Nursing News branded backdrop
Photo of a man with glasses in a suit in front of an Oncology Nursing News backdrop
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
Image of a woman with glasses wearing a striped blouse and a black sweater in front of an Oncology Nursing News branded backdrop
Photo of Jamie Carroll, APRN, CNP, MSN, from a video call with an Oncology Nursing News branded border around the frame
Image of Kayle Freeman, DNP, APRN, FNP-C, in a video call with an Oncology Nursing News border around the frame
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
Image of Pattie Jakel, MN, RN, AOCN, in front of a blue watercolor Oncology Nursing News backdrop
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
Medium closeup shot of a women in front of a dark blue background with graphics that read "All in Against Cancer" and "Ochsner Health"
Related Content
Graphic reading "FDA APPROVED" resembling a stamp of approval

Cabozantinib Approved for Unresectable, Advanced/Metastatic epNET and pNET

Bridget Hoyt
March 26th 2025
Article

The FDA approved cabozantinib for use in patients with previously treated unresectable, locally advanced or metastatic, well-differentiated epNETs or pNETs.

The Vitals

ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment

Lindsay Fischer
October 31st 2023
Podcast

Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.

Image of a vaccine being prepared by a person in a white coat and blue gloves

Maintenance OSE2101 With Chemo Reaches Primary OS End Point in PDAC

Kyle Doherty
Published: March 24th 2025 | Updated: March 24th 2025
Article

Maintenance treatment with OSE2101 plus FOLFIRI following induction chemotherapy with FOLFIRINOX yielded promising results in patients with advanced/metastatic PDAC.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Lindsay Fischer
October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

Illustration of small patient and provider characters surrounded by larger technology devices with medical information coming off of the screens and other medical props nearby

Mobile App May Be Feasible for Tracking Oral Cancer Medication Adherence

Bridget Hoyt
March 10th 2025
Article

Although participants in the study had greater rates of nonadherence postintervention, those who reported nonadherence at baseline saw some increase in adherence.

Anatomical diagram of a person with the gastrointestinal tract highlighted in orange

OS Benefit With T-DXd in Unresectable/Metastatic HER2+ Gastric/GEJ Adenocarcinoma

Chris Ryan
March 6th 2025
Article

T-DXd delivered an OS benefit for patients with unresectable or metastatic HER2-positive gastric and GEJ adenocarcinoma following trastuzumab-based treatment.